Literature DB >> 7856090

Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators.

S J Madore1, B R Cullen.   

Abstract

The Tat regulatory protein encoded by human immunodeficiency virus type 1 (HIV-1) induces high levels of transcription from the viral long terminal repeat (LTR) promoter element after interacting with a promoter proximal RNA target sequence. In the wild-type HIV-1 LTR, this activation is facilitated by the synergistic interaction of Tat with the NF-kappa B and, particularly, SP1 regulatory proteins that bind to DNA sequences within the LTR promoter element. Using a synthetic Tat responsive indicator construct, we here demonstrate that NF-kappa B and SP1 are not uniquely or even unusually competent to synergize with HIV-1 Tat. Instead, these proteins can be functionally replaced by several, but not all, of the heterologous cellular and viral transcriptional activators tested. Tat therefore shares the ability to functionally synergize with a range of transcriptional activators, which is characteristic of DNA-sequence-specific regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856090     DOI: 10.1006/viro.1995.1041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles.

Authors:  P Shannon Pendergrast; Chen Wang; Nouria Hernandez; Sui Huang
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

2.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.

Authors:  M O Gold; X Yang; C H Herrmann; A P Rice
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.

Authors:  T P Cujec; H Okamoto; K Fujinaga; J Meyer; H Chamberlin; D O Morgan; B M Peterlin
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

5.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

7.  Synergistic enhancement of both initiation and elongation by acidic transcription activation domains.

Authors:  W S Blair; R A Fridell; B R Cullen
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

8.  Activation domains of transcription factors mediate replication dependent transcription from a minimal HIV-1 promoter.

Authors:  R D Williams; B A Lee; S P Jackson; N J Proudfoot
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

9.  Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.

Authors:  S L Schafer; J Vlach; P M Pitha
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.